Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The company's key products, including Ozempic (semaglutide ... such as Amycretin, an oral GLP-1/Amylin co-agonist that has shown competitive weight loss percentages in early trials.

With weight loss drugs like Ozempic and Mounjaro becoming widespread, it can be tempting to look for a quick fix. Official stats on how many Brits are using semaglutides, which mimic the action of the ...

With weight loss drugs like Ozempic and Mounjaro becoming widespread, it can be tempting to look for a quick fix. Official stats on how many Brits are using semaglutides, which mimic the action of ...

Fresh questions are being asked about the use of weight loss ... its stronger dose form, branded as Wegovy, could help users lose 15% of their body weight in 68 weeks. Ozempic is only prescribed ...